Answers are grounded in this paper and cite their sources.
Phase 1 clinical trial evaluates safety and pharmacokinetics of CG2001 in male subjects, suggesting its potential as a treatment option.
The favorable safety profile and reduced systemic finasteride exposure position CG2001 as a promising alternative, supporting further clinical development in a phase IIa trial, and provide a pharmacokinetic foundation for subsequent efficacy trials in patients with AGA.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: